Researchers at the Harvard T.H. Chan School of Public Health linked commercial Fitbit records with clinical biomarkers from the All of Us Research Program. The dataset covered 2,222 people and 8,447 person-years. Activity records yielded measures of the intensity, timing and regularity of rest–activity rhythms, while biological age was estimated with PhenoAge.

Stronger rhythm intensity was associated with 26–46% lower odds of accelerated aging by PhenoAge. Associations involving timing and regularity differed by sex. These are observational associations, however: the study does not show that changing one’s routine will itself reduce biological age, and a consumer wearable is not a diagnostic device.

A realistic application could be a low-cost longitudinal digital marker that complements occasional laboratory tests. If replicated, it might help researchers or clinicians notice when a person’s rhythm is deteriorating over time and select who may benefit from closer assessment or a prevention programme. An activity curve alone must not determine a diagnosis or treatment.

Deployment will require validation in more diverse populations and across device types, while separating the effects of shift work, illness, medication, season and social conditions. Prospective studies must also show whether changes in the marker predict later health outcomes beyond established risk factors.

Our optimistic editorial estimate is that validated research or prevention tools could emerge within 2–4 years. Routine clinical assessment of biological aging from an ordinary wristband would probably require 5–10 years of standardisation and clinical validation; the study itself promises no timetable.